Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT00918255. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
Study identification
- NCT ID
- NCT00918255
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Abbott
- Industry
- Enrollment
- 154 participants
Conditions and interventions
Conditions
Interventions
- adalimumab Biological
- Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2009
- Primary completion
- Feb 28, 2010
- Completion
- Oct 31, 2010
- Last update posted
- May 8, 2011
2009 – 2010
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Ref # / Investigator 19062 | Birmingham | Alabama | 35205 | — |
| Site Ref # / Investigator 18201 | Bakerfield | California | 93309 | — |
| Site Ref # / Investigator 18467 | Los Angeles | California | 90045 | — |
| Site Ref # / Investigator 18207 | San Diego | California | 92103 | — |
| Site Ref # / Investigator 18204 | Miami | Florida | 33136 | — |
| Site Ref # / Investigator 18209 | Atlanta | Georgia | 30327 | — |
| Site Ref # / Investigator 18202 | Skokie | Illinois | 60077 | — |
| Site Ref # / Investigator 18211 | Evansville | Indiana | 47714 | — |
| Site Ref # / Investigator 18203 | Boston | Massachusetts | 02111 | — |
| Site Ref # / Investigator 18210 | Boston | Massachusetts | 02114 | — |
| Site Ref # / Investigator 18461 | St Louis | Missouri | 63104 | — |
| Site Ref # / Investigator 18466 | Omaha | Nebraska | 68144 | — |
| Site Ref # / Investigator 19141 | New York | New York | 10016 | — |
| Site Ref # / Investigator 18208 | New York | New York | 10019 | — |
| Site Ref # / Investigator 19001 | Winston-Salem | North Carolina | 27103 | — |
| Site Ref # / Investigator 18981 | Hershey | Pennsylvania | 17033 | — |
| Site Ref # / Investigator 18464 | Philadelphia | Pennsylvania | 19104 | — |
| Site Ref # / Investigator 19061 | Dallas | Texas | 75246-1613 | — |
| Site Ref # / Investigator 18463 | San Antonio | Texas | 78258 | — |
| Site Ref # / Investigator 18206 | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00918255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2011 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00918255 live on ClinicalTrials.gov.